ONWARD Medical's 2025 Performance and Pipeline Developments

ONWARD Medical reported its 2025 financial and operational outcomes, showcasing a solid US commercial presence and notable pipeline progress. The company sold 117 ARC-EX® Systems to over 80 US rehabilitation clinics, establishing significant market momentum. Regulatory highlights include receiving CE Mark for the ARC-EX System for clinic and home use, and FDA clearance for its home use in the US. Additionally, the FDA approved an investigational device exemption for ARC-IM®, advancing the Empower BP global pivotal study.

The company also made strides in science and technology, publishing in prominent journals and performing four ARC-BCI® Therapy trials. Financially, ONWARD Medical reported EUR 5.4 million in revenue, with equity capital increased by EUR 50.8 million. It closed the year with EUR 68.1 million in net cash.